Table 1 Characteristics of patients according to the 2015 ATA risk-stratification system in the postoperative setting
LR (n = 395) | IR (n = 202) | HR (n = 21) | p | |
|---|---|---|---|---|
Mean age ± SD (yrs) | 49 ± 15 | 51 ± 18 | 67 ± 10 | <.0001 |
Sex ratio (Female) | 3.8 (79%) | 2.0 (67%) | 2.5 (71%) | 0.005 |
Mean tumor size ± SD (mm) | 22 ± 15 | 25 ± 18 | 51 ± 34 | <.0001 |
Histology | ||||
PTC | 348 (88%) | 169 (84%) | 11 (52%) | <.0001 |
FTC | 47 (12%) | 12 (6%) | 4 (19%) | |
PDTC | 0 | 21 (10%) | 6 (29%) | |
Aggressive pathological subtypes | <.001 | |||
No | 395 (100%) | 172 (85%) | 18 (86%) | |
Yes | 0 | 30 (15%) | 3 (14%) | |
Extra-thyroidal extension | <.0001 | |||
Minimal | 0 | 91 (45%) | 1 (5%) | |
Gross | 0 | 0 | 14 (67%) | |
T status (TNM 2017) | <.0001 | |||
T1a + T1b | 230 (58%) | 112 (56%) | 1 (5%) | |
T2 | 152 (39%) | 57 (28%) | 4 (19%) | |
T3a + T3b | 13 (3%) | 33 (16%) | 2 (9%) | |
T4a + T4b | 0 | 0 | 14 (67%) | |
N status (TNM 2017) | <.0001 | |||
Nx | 249 (63%) | 31 (15%) | 6 (28%) | |
N0 | 119 (30%) | 27 (13%) | 5 (24%) | |
N1a + N1b | 27 (7%) | 144 (72%) | 10 (48%) | |
M status (TNM 2017) | <.0001 | |||
M0 | 395 (100%) | 202 (100%) | 10 (48%) | |
M1 | 0 | 0 | 11 (52%) | |
Positive TgAb level | 48 (12%) | 32 (16%) | 2 (10%) | 0.43 |
Stimulated Tg level at RAI treatment (range)a | 1.9 (0.1–744.0) | 6.4 (0.1–4340.0) | 126.2 (0.4–58,690.0) | <.0001 |